Tango Therapeutics, Inc (TNGX)
22.52
-0.24 (1.05%)
Upcoming Events
Latest Headlines
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026 4:05 PM - StreetInsider
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 1, 2026 7:00 AM - StreetInsider
Tango Therapeutics Inc. (TNGX) PT Raised to $68 at H.C. Wainwright
August 18, 2026 6:39 AM - StreetInsider
Tango Therapeutics Inc. (TNGX) Reiterated at Buy by Stifel: 3 Catalysts by YE26
August 17, 2026 7:49 AM - StreetInsider
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Nextech Crossover I GP S.a r.l.
August 14, 2026 4:49 PM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: TCG Crossover GP II, LLC
August 14, 2026 4:20 PM - SEC Filing
Form SCHEDULE 13G Tango Therapeutics, Inc. Filed by: GOLDMAN SACHS GROUP INC
August 14, 2026 2:12 PM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Woodline Partners LP
August 14, 2026 11:05 AM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 14, 2026 8:24 AM - SEC Filing
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
August 12, 2026 12:02 PM - SEC Filing
Tango Therapeutics Inc. (TNGX) PT Raised to $35 at Guggenheim
August 12, 2026 6:53 AM - StreetInsider
Form 8-K Tango Therapeutics, Inc. For: Aug 11
August 11, 2026 5:13 PM - SEC Filing
Form 424B5 Tango Therapeutics, Inc.
August 11, 2026 5:11 PM - SEC Filing
NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float
August 11, 2026 11:01 AM - StreetInsider
Tango Therapeutics, Inc. (TNGX) Misses Q2 EPS by 5c
August 11, 2026 7:27 AM - StreetInsider
Form 8-K Tango Therapeutics, Inc. For: Aug 11
August 11, 2026 7:21 AM - SEC Filing
Form 10-Q Tango Therapeutics, Inc. For: Jun 30
August 11, 2026 7:13 AM - SEC Filing
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 11, 2026 7:00 AM - StreetInsider
Form 8-K/A Tango Therapeutics, Inc. For: Jul 31
August 7, 2026 6:42 AM - SEC Filing
Tango Therapeutics Announces Executive Chair Transition
August 6, 2026 6:24 PM - Globe NewsWire
Form 8-K Tango Therapeutics, Inc. For: Jul 31
August 6, 2026 5:30 PM - SEC Filing
Form 4 Tango Therapeutics, Inc. For: Aug 03 Filed by: Crystal Adam
August 5, 2026 4:01 PM - SEC Filing
Form 144 Tango Therapeutics, Inc. Filed by: Crystal Adam
August 3, 2026 4:47 PM - SEC Filing
Tango Therapeutics Inc. (TNGX) PT Raised to $40 at Mizuho
July 17, 2026 6:34 AM - StreetInsider
JPMorgan Starts Tango Therapeutics Inc. (TNGX) at Overweight
July 15, 2026 3:01 AM - StreetInsider
Form 4 Tango Therapeutics, Inc. For: Jul 01 Filed by: Crystal Adam
July 2, 2026 7:24 PM - SEC Filing
Tango Therapeutics Inc. (TNGX) PT Raised to $46 at Canaccord
June 29, 2026 4:06 AM - StreetInsider
Jefferies Upgrades Tango Therapeutics Inc. (TNGX) to Buy
June 25, 2026 4:03 PM - StreetInsider
Form 4 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert
June 23, 2026 6:11 PM - SEC Filing
Form 3 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert
June 23, 2026 6:04 PM - SEC Filing
Form 8-K Tango Therapeutics, Inc. For: Jun 19
June 23, 2026 5:19 PM - SEC Filing
Tango Therapeutics adds Robert Azelby to its board of directors
June 22, 2026 4:05 PM - StreetInsider
Tango Therapeutics Appoints Robert Azelby to Board of Directors
June 22, 2026 4:05 PM - StreetInsider
Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP
June 17, 2026 4:46 PM - SEC Filing
Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella
June 11, 2026 6:01 PM - SEC Filing
Form 8-K Tango Therapeutics, Inc. For: Jun 09
June 10, 2026 5:22 PM - SEC Filing
Form 424B5 Tango Therapeutics, Inc.
June 10, 2026 5:21 PM - SEC Filing
Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella
June 10, 2026 4:46 PM - SEC Filing
Tango Therapeutics Inc. (TNGX) PT Raised to $66 at H.C. Wainwright
June 10, 2026 7:11 AM - StreetInsider
Form FWP Tango Therapeutics, Inc. Filed by: Tango Therapeutics, Inc.
June 10, 2026 6:03 AM - SEC Filing
Tango Therapeutics prices $600 million public offering at $30 per share
June 9, 2026 10:49 PM - StreetInsider
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
June 9, 2026 10:49 PM - Globe NewsWire
Tango Therapeutics Inc. (TNGX) PT Raised to $35 at B.Riley
June 9, 2026 8:28 AM - StreetInsider
Tango Therapeutics Inc. (TNGX) PT Raised to $42 at Canaccord
June 9, 2026 6:50 AM - StreetInsider
Form 4 Tango Therapeutics, Inc. For: Jun 05 Filed by: Ketchum John B
June 8, 2026 6:08 PM - SEC Filing
Form 4 Tango Therapeutics, Inc. For: Jun 05 Filed by: Calhoun Lesley Ann
June 8, 2026 6:01 PM - SEC Filing
Form 4 Tango Therapeutics, Inc. For: Jun 05 Filed by: Rothenberg Mace
June 8, 2026 5:55 PM - SEC Filing
Form 4 Tango Therapeutics, Inc. For: Jun 05 Filed by: Lee Sung
June 8, 2026 5:49 PM - SEC Filing
Form 424B5 Tango Therapeutics, Inc.
June 8, 2026 4:16 PM - SEC Filing
Tango Therapeutics launches $500 million public stock offering
June 8, 2026 4:01 PM - StreetInsider
Tango Therapeutics Announces Proposed $500 Million Public Offering
June 8, 2026 4:01 PM - StreetInsider
Tango Therapeutics Inc. (TNGX) PT Raised to $36 at Mizuho
June 8, 2026 12:26 PM - StreetInsider
Wolfe Research Upgrades Tango Therapeutics Inc. (TNGX) to Outperform, 'Vopi Finds Its Dance Partner'
June 8, 2026 11:40 AM - StreetInsider
Form 8-K Tango Therapeutics, Inc. For: Jun 08
June 8, 2026 7:16 AM - SEC Filing
Tango drug combination shows 92% response rate in pancreatic cancer trial
June 8, 2026 7:00 AM - StreetInsider
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
June 8, 2026 6:59 AM - Globe NewsWire
Full Article List
